Compare Heron Therapeutics Inc (HRTX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Yum! Brands, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Yum! Brands, Inc. trades at $145.04 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 573.7× Heron Therapeutics Inc's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Yum! Brands, Inc. for 132 Days on average.
| HRTX | YUM | |
|---|---|---|
Market Cap | $68.01M | $39.02B |
Volume | 1,891,941 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $168.16 |
52-Week Low | $0.27 | $135.77 |
Typical Hold Time | 35 Days | 132 Days |
Enterprise Value | $174.75M | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
YUM stock trades at $145.15, up 3.42% today, with a bullish technical signal and strong support at $141. Revenue grew to $8.21B in 2025, with net income of $1.56B and a 25.4% net margin. The company recently sold Pizza Hut for $1.5B, focusing on KFC and Taco Bell, and declared a $0.75 dividend payable September 18, 2026.
Outlook is positive with a consensus price target of $170.44, though high debt and competitive pressures pose risks. Earnings beat expectations in two of the last three quarters, and cash flow from operations is robust at $2.01B, supporting shareholder returns amid a hold-heavy analyst rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
